Live Breaking News & Updates on First Allogeneic Stem Cell Therapy

Stay updated with breaking news from First allogeneic stem cell therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn's Disease

Takeda Pharmaceutical Company Limited
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn s Disease
Wednesday, February 10, 2021 12:15PM IST (6:45AM GMT)

Takeda Applies for Approval for the Company’s First Allogeneic Stem Cell Therapy in Japan
If Approved, Darvadstrocel Would Offer a Potential Cell-Mediated Closure Option for Adult Patients in Japan Who Do Not Respond to Conventional or Biologic Therapies for Complex Perianal Fistulas in Crohn’s Disease
1,2
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (development code: Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease (CD). ....

Jammu And Kashmir , United States , United Kingdom , Van Assche , Kazumi Kobayashi , Perianal Fistulising Crohn , Ann Gastroenterol , Naoyoshi Hirota , Luke Willats , Takeda Pharmaceuticals United States Inc , Takeda Pharmaceutical Company Limited , Admire Cd Study Group Collaborators , European Commission , Drug Administration , Takeda Pharmaceutical Company , Exchange Commission , Japan Ministry Of Health , Japanese Ministry Of Health , European Union , Takeda Development Center Japan , First Allogeneic Stem Cell Therapy , Darvadstrocel Would Offer , Potential Cell Mediated Closure Option , Adult Patients , Japan Who Do Not Respond , Biologic Therapies ,

Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients wit

Search jobs
10-Feb-2021
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel
In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease

−

Who Do Not Respond to Conventional or Biologic Therapies for Complex Perianal Fistulas in Crohn’s Disease[i]

Osaka, JAPAN, February 10, 2021 –Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (development code: Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease (CD) ....

Van Assche , Ann Gastroenterol , Naoyoshi Hirota , Perianal Fistulising Crohn , Japan Ministry Of Health , Japanese Ministry Of Health , Takeda Pharmaceutical Company Limited , Admire Cd Study Group Collaborators , Takeda Development Center Japan , Takeda Submits New Drug Application , Market Darvadstrocel , Complex Perianal Fistulas , Adult Patients , Takeda Applies , First Allogeneic Stem Cell Therapy , Darvadstrocel Would Offer , Potential Cell Mediated Closure Option , Japanwho Do Not Respond , Biologic Therapies , Japanese Ministry , Japanese Study , General Manager , Subjects With Complex Perianal Fistulising Crohn , Dis Colon , ஜப்பான் அமைச்சகம் ஆஃப் ஆரோக்கியம் , ஜப்பானிய அமைச்சகம் ஆஃப் ஆரோக்கியம் ,